Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. administers 470.3 mln doses of COVID-19 vaccines -CDC

12/05/2021 | 03:40pm EST

Dec 5 (Reuters) - The United States had administered 470,297,846 doses of COVID-19 vaccines in the country as of Sunday morning and distributed 580,417,105 doses, the U.S. Centers for Disease Control and Prevention said.

The number of doses administered was up from 468,516,782 as reported on Saturday, the CDC said.

The number of doses delivered, however, was marginally down from the numbers reported on Saturday. The CDC said previously that revisions made by vaccine providers can result in cumulative delivery data dropping between certain days.

The agency said 235,698,738 people had received at least one dose, while 198,962,520 people were fully vaccinated as of 6 a.m. EST on Sunday.

The CDC tally includes two-dose vaccines from Moderna Inc and Pfizer Inc/BioNTech as well as Johnson & Johnson's one-shot vaccine.

About 46.3 million people had received a booster dose of either Pfizer, Moderna or Johnson & Johnson's COVID-19 vaccine. Booster doses from Moderna and Johnson & Johnson were authorized by the U.S. health regulator on Oct. 20. (Reporting by Baranjot Kaur in Bengaluru; Editing by Peter Cooney)


ę Reuters 2021
All news about MODERNA, INC.
01/28Easier to produce COVID vaccine shows promise in trials; nasal spray vaccine booster wo..
RE
01/28SVB Leerink Adjusts Moderna's Price Target to $85 From $86, Maintains Underperform Rati..
MT
01/28Moderna, Pfizer Boosters Provide High Level of Protection Against Omicron, UK Health Se..
MT
01/27Pfizer/BioNTech, Moderna COVID-19 Booster Shots Provide Protection Against Death from O..
MT
01/27Moderna, IAVI Say Clinical Trial of Experimental HIV Vaccine Antigens is Underway
MT
01/27MODERNA : IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Tec..
PU
01/27WALL STREET STOCK EXCHANGE : Are we still in the Goldilocks zone?
01/27MARKETSCREENER'S WORLD PRESS REVIEW : January 27, 2022
01/26Pfizer-BioNTech, Moderna COVID-19 Jabs Shown Safe For Women Undergoing IVF in Study
MT
01/26Moderna Launches Mid-Stage Study of Omicron-Specific Booster Jab
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 766 M - -
Net income 2021 11 257 M - -
Net cash 2021 11 938 M - -
P/E ratio 2021 6,00x
Yield 2021 -
Capitalization 64 657 M 64 657 M -
EV / Sales 2021 2,97x
EV / Sales 2022 1,93x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 159,47 $
Average target price 262,47 $
Spread / Average Target 64,6%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-37.21%64 657
LONZA GROUP AG-17.41%50 233
IQVIA HOLDINGS INC.-15.35%45 624
SEAGEN INC.-17.45%23 336
ICON PUBLIC LIMITED COMPANY-15.10%21 404
CELLTRION, INC.-23.74%17 399